{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:50:25Z","timestamp":1791323425591,"version":"4.3.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2016-02361157"],"award-info":[{"award-number":["RF-2016-02361157"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To compare transarterial embolization (TAE) and drug-eluting microspheres transarterial chemoembolization (DEM-TACE) in the treatment of hepatocellular carcinoma (HCC) through a non-inferiority randomized clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Patients diagnosed with unresectable HCC were randomly assigned to either the TAE or DEM-TACE group. The primary endpoint was time to progression (TTP), and secondary endpoints included overall survival, hospitalization stay, tumor response rates, and severe adverse events (SAE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At the end of the trial, a total of 111 patients (56 TAE and 55 DEM-TACE) were enrolled between 2019 and 2022. The median TTP was similar between TAE and DEM-TACE (7.56 vs. 7.98\u00a0months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.432). In patients with confirmed disease progression, the mean TTP was 6.68 vs. 8.43\u00a0months for TAE and DEM-TACE, respectively, with a mean difference of 1.75\u00a0months (95% CI \u2212\u20091.47\u20134.97), falling within the predefined equivalence range; two one side test (TOST) analysis confirmed equivalence (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.022 for lower and upper bounds. Overall survival, tumor response rates, and adverse events were also not statistically different between groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05 for each outcome). Finally, Days of hospitalization were not statistically different (median 4\u00a0days for both arms,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.638).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TAE and DEM-TACE had comparable results in the treatment of early and intermediate stage unresectable HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00270-026-04487-3","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T20:46:12Z","timestamp":1781037972000},"page":"2052-2061","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transarterial Embolization Alone Versus Drug-Eluting Microspheres Chemoembolization for\u00a0Hepatocellular Carcinoma\u00a0(RAD-18-TAcE): A Multicenter Randomized Clinical Trial"],"prefix":"10.1007","volume":"49","author":[{"given":"Cristina","family":"Mosconi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2699-7128","authenticated-orcid":false,"given":"Makoto","family":"Taninokuchi Tomassoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Zanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandro","family":"Paccapelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Marasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Gusmini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Sironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Muglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Mario Edgardo","family":"Fronda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Calandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doriguzzi Breatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cucchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Cobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Renzulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"4487_CR1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","volume":"161","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Ferlay J, De Martel C, Georges D, Ibrahim AS, Zheng R, et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 2022;161:108\u201318. https:\/\/doi.org\/10.1016\/j.ejca.2021.11.023.","journal-title":"Eur J Cancer"},{"key":"4487_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1053\/j.ro.2016.02.005","volume":"51","author":"A Makramalla","year":"2016","unstructured":"Makramalla A, Itri JN, Choe KA, Ristagno RL. Transarterial therapies for hepatocellular carcinoma. Semin Roentgenol. 2016;51:95\u2013105. https:\/\/doi.org\/10.1053\/j.ro.2016.02.005.","journal-title":"Semin Roentgenol"},{"key":"4487_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"B Sangro","year":"2025","unstructured":"Sangro B, Argemi J, Ronot M, Paradis V, Meyer T, Mazzaferro V, et al. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82:315\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.028.","journal-title":"J Hepatol"},{"key":"4487_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","journal-title":"J Hepatol"},{"key":"4487_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","volume":"72","author":"J-L Raoul","year":"2019","unstructured":"Raoul J-L, Forner A, Bolondi L, Cheung TT, Kloeckner R, De Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28\u201336. https:\/\/doi.org\/10.1016\/j.ctrv.2018.11.002.","journal-title":"Cancer Treat Rev"},{"key":"4487_CR6","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.2217\/fon-2018-0136","volume":"14","author":"F Melchiorre","year":"2018","unstructured":"Melchiorre F, Patella F, Pescatori L, Pesapane F, Fumarola E, Biondetti P, et al. DEB-TACE: a standard review. Future Oncol. 2018;14:2969\u201384. https:\/\/doi.org\/10.2217\/fon-2018-0136.","journal-title":"Future Oncol"},{"key":"4487_CR7","doi-asserted-by":"publisher","first-page":"S211","DOI":"10.1016\/S1051-0443(07)61789-8","volume":"13","author":"DE Ramsey","year":"2002","unstructured":"Ramsey DE, Kernagis LY, Soulen MC, Geschwind J-FH. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2002;13:S211\u201321. https:\/\/doi.org\/10.1016\/S1051-0443(07)61789-8.","journal-title":"J Vasc Interv Radiol"},{"key":"4487_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143351","volume":"14","author":"T Garg","year":"2022","unstructured":"Garg T, Shrigiriwar A, Habibollahi P, Cristescu M, Liddell RP, Chapiro J, et al. Intraarterial therapies for the management of hepatocellular carcinoma. Cancers Basel. 2022;14:3351. https:\/\/doi.org\/10.3390\/cancers14143351.","journal-title":"Cancers Basel"},{"key":"4487_CR9","doi-asserted-by":"publisher","first-page":"052","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet J. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:052\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132.","journal-title":"Semin Liver Dis"},{"key":"4487_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00270-025-04200-w","volume":"49","author":"D Filippiadis","year":"2025","unstructured":"Filippiadis D, Pereira PL, Hausegger KA, Ryan AG, Binkert CA. CIRSE standards of practice for the classification of complications: the modified CIRSE classification system. Cardiovasc Intervent Radiol. 2025;49:2\u20136. https:\/\/doi.org\/10.1007\/s00270-025-04200-w.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"4487_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/bjc.2014.199","volume":"111","author":"R Golfieri","year":"2014","unstructured":"Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255\u201364. https:\/\/doi.org\/10.1038\/bjc.2014.199.","journal-title":"Br J Cancer"},{"key":"4487_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123166","volume":"15","author":"A Lawson","year":"2023","unstructured":"Lawson A, Kamarajah SK, Parente A, Pufal K, Sundareyan R, Pawlik TM, et al. Outcomes of transarterial embolisation (TAE) vs. transarterial chemoembolisation (TACE) for hepatocellular carcinoma: a systematic review and meta-analysis. Cancers Basel. 2023;15:3166. https:\/\/doi.org\/10.3390\/cancers15123166.","journal-title":"Cancers Basel"},{"key":"4487_CR13","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/BF00687096","volume":"31","author":"S Kawai","year":"1992","unstructured":"Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma? a comparison of lipiodol-transcatheter arterial embolization with and without Adriamycin (first cooperative study). Cancer Chemother Pharmacol. 1992;31:S1-6. https:\/\/doi.org\/10.1007\/BF00687096.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4487_CR14","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Monta\u00f1a X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(02)08649-X.","journal-title":"Lancet"},{"key":"4487_CR15","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jhep.2012.07.017","volume":"57","author":"MJ Song","year":"2012","unstructured":"Song MJ, Chun HJ, Song DS, Kim HY, Yoo SH, Park C-H, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012;57:1244\u201350. https:\/\/doi.org\/10.1016\/j.jhep.2012.07.017.","journal-title":"J Hepatol"},{"key":"4487_CR16","doi-asserted-by":"publisher","DOI":"10.3892\/or.2012.1651","author":"F Recchia","year":"2012","unstructured":"Recchia F. Chemoembolization of unresectable hepatocellular carcinoma: decreased toxicity with slow-release doxorubicin-eluting beads compared with lipiodol. Oncol Rep. 2012. https:\/\/doi.org\/10.3892\/or.2012.1651.","journal-title":"Oncol Rep"},{"key":"4487_CR17","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.jvir.2011.07.002","volume":"22","author":"R Sacco","year":"2011","unstructured":"Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2011;22:1545\u201352. https:\/\/doi.org\/10.1016\/j.jvir.2011.07.002.","journal-title":"J Vasc Interv Radiol"},{"key":"4487_CR18","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.rx.2010.07.010","volume":"53","author":"MD Ferrer Puchol","year":"2011","unstructured":"Ferrer Puchol MD, La Parra C, Esteban E, Va\u00f1o M, Forment M, Vera A, et al. Quimioembolizaci\u00f3n del hepatocarcinoma: part\u00edculas cargadas frente a quimioembolizaci\u00f3n convencional. Radiologia. 2011;53:246\u201353. https:\/\/doi.org\/10.1016\/j.rx.2010.07.010.","journal-title":"Radiologia"},{"key":"4487_CR19","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1159\/000525500","volume":"11","author":"M Ikeda","year":"2022","unstructured":"Ikeda M, Arai Y, Inaba Y, Tanaka T, Sugawara S, Kodama Y, et al. Conventional or drug-eluting beads? randomized controlled study of chemoembolization for hepatocellular carcinoma: JIVROSG-1302. Liver Cancer. 2022;11:440\u201350. https:\/\/doi.org\/10.1159\/000525500.","journal-title":"Liver Cancer"},{"key":"4487_CR20","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.21037\/jgo-23-261","volume":"14","author":"M Cathomas","year":"2023","unstructured":"Cathomas M, Mueller F, Mertineit N, Baumgartner I, Candinas D, Berzigotti A, et al. Comparison of transarterial bland embolization and drug-eluting beads transarterial chemoembolization for very early and early hepatocellular carcinoma not amenable for surgery or ablation: a single center retrospective data analysis. J Gastrointest Oncol. 2023;14:2167\u201377. https:\/\/doi.org\/10.21037\/jgo-23-261.","journal-title":"J Gastrointest Oncol"},{"key":"4487_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00270-009-9750-0","volume":"33","author":"K Malagari","year":"2010","unstructured":"Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with beadblock for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010;33:541\u201351. https:\/\/doi.org\/10.1007\/s00270-009-9750-0.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"4487_CR22","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1200\/JCO.2015.64.0821","volume":"34","author":"KT Brown","year":"2016","unstructured":"Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol. 2016;34:2046\u201353. https:\/\/doi.org\/10.1200\/JCO.2015.64.0821.","journal-title":"J Clin Oncol"},{"key":"4487_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00270-022-03335-4","volume":"46","author":"G Andreozzi","year":"2023","unstructured":"Andreozzi G, Lorenzoni V, Bargellini I, Cioni R, Turchetti G. Drug-eluting microspheres compared to conventional transarterial chemoembolization as first line treatment for unresectable hepatocellular carcinoma: a single-center retrospective cost-utility analysis. Cardiovasc Intervent Radiol. 2023;46:319\u201326. https:\/\/doi.org\/10.1007\/s00270-022-03335-4.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"4487_CR24","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/2050640616673516","volume":"5","author":"A Facciorusso","year":"2017","unstructured":"Facciorusso A, Bellanti F, Villani R, Salvatore V, Muscatiello N, Piscaglia F, et al. Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta\u2010analysis of randomized trials. United Eur Gastroenterol J. 2017;5:511\u20138. https:\/\/doi.org\/10.1177\/2050640616673516.","journal-title":"United Eur Gastroenterol J"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-026-04487-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-026-04487-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-026-04487-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:00:22Z","timestamp":1791320422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-026-04487-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":24,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4487"],"URL":"https:\/\/doi.org\/10.1007\/s00270-026-04487-3","relation":{},"ISSN":["1432-086X"],"issn-type":[{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest relevant to this study.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}